CONSOL Energy, Inc. (NYSE:CNX) will unveil its latest earnings on Thursday, January 26, 2012. The average estimate of analysts is for net income of 62 cents per share, a rise of 14.8% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 60 cents. Between one and three months ago, the average estimate moved up. It has been unchanged at 62 cents during the last month. For the year, analysts are projecting profit of $2.95 per share, a rise of 31.1% from last year.

Last quarter, the company topped estimates by 0 cents, coming in at net income of 73 cents per share against a mean estimate of profit of 67 cents. The company fell in line with estimates in the second quarter. Analysts are projecting a rise of 5.9% in revenue from the year-earlier quarter to $1.44 billion.

Competitors to Watch: Peabody Energy Corporation (NYSE:BTU), Arch Coal, Inc. (NYSE:ACI), Alliance Holdings GP, L.P. (NASDAQ:AHGP), Intl. Coal Group, Inc. (NYSE:ICO), Patriot Coal Corporation (NYSE:PCX), Massey Energy Company (NYSE:MEE), Natural Resource Partners LP (NYSE:NRP), Alpha Natural Resources, Inc. (NYSE:ANR), James River Coal Company (NASDAQ:JRCC), and Oxford Resource Partners, LP (NYSE:OXF).

Zimmer Holdings, Inc. (NYSE:ZMH) will unveil its latest earnings on Thursday, January 26, 2012. The average estimate of analysts is for net income of $1.34 per share, a rise of 5.5% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.35. Between one and three months ago, the average estimate moved down. It has been unchanged at $1.34 during the last month. For the year, analysts are projecting profit of $4.78 per share, a rise of 10.4% from last year.

Last quarter, the company beat estimates by one cent, coming in at net income of $1.04 a share versus the estimate of profit of $1.03 a share. It marked the fourth straight quarter of beating estimates. Analysts are projecting a rise of 2.7% in revenue from the year-earlier quarter to $1.16 billion.

Competitors to Watch: Stryker Corporation (NYSE:SYK), Exactech, Inc. (NASDAQ:EXAC), Wright Medical Group, Inc. (NASDAQ:WMGI), RTI Biologics Inc. (NASDAQ:RTIX), Tornier N.V. (NASDAQ:TRNX), Smith & Nephew plc (NYSE:SNN), MAKO Surgical Corp. (NASDAQ:MAKO), NuVasive, Inc. (NASDAQ:NUVA), TranS1 Inc. (NASDAQ:TSON), and Alphatec Holdings, Inc. (NASDAQ:ATEC).

Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!